Business
Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis
PALO ALTO, Calif., September 09, 2025--Varian, a Siemens Healthineers company, announced today that its Embozene microspheres have received CE Marking for Genicular Artery Embolisation (GAE) for knee osteoarthritis. This regulatory milestone makes Embozene the first—and only—embolic agent to be CE Marked specifically for GAE, a minimally invasive procedure intended to target inflammation and help relieve pain in patients with knee osteoarthritis.
About this update from Siemens Healthineers Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":229,"url":"https://media.zenfs.com/en/business-wire.com/9bd498d0a274f3d9cb6ffde0baeb8241"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a1RHnTLGvHa0bdjJK2M5jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ1ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9bd498d0a274f3d9cb6ffde0baeb8241","width":480,"height":229}},"lazy":false},{"type":"text","content":"PALO ALTO, Calif., September 09, 2025--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, announced today that its Embozene microspheres have received CE Marking for Genicular Artery Embolisation (GAE) for knee osteoarthritis. This regulatory milestone makes Embozene the first—and only—embolic agent to be CE Marked specifically for GAE, a minimally invasive procedure intended to target inflammation and help relieve pain in patients with knee osteoarthritis.","length":467,"tagName":"p"},{"type":"text","content":"Knee osteoarthritis is widespread, with a reported prevalence of nearly 375 million cases globally¹ and can significantly impair physical function and quality of life. While current treatments – such as physical therapy, medications, and intra-articular injections – offer temporary relief, many patients are not yet ready for, or wish to delay, total knee replacement surgery. This gap in care highlights the need for new options that can help patients manage pain and maintain function.","length":488,"tagName":"p"},{"type":"text","content":"GAE is designed to help fill that gap. The procedure involves advancing a small catheter into the genicular arteries—tiny vessels that supply the knee joint and contribute to inflammation—and delivering Embozene microspheres to reduce blood flow to areas of greatest inflammation, with the goal of pain relief.","length":310,"tagName":"p"},{"type":"text","content":"By enabling Genicular Artery Embolisation with Embozene microspheres, Varian aims to support patients who have exhausted other measures and seek alternatives to joint replacement surgery. This milestone underscores Varian’s continued investment and commitment to advancing innovative, image-guided therapies that improve patient outcomes and expand treatment options for chronic musculoskeletal conditions.","length":406,"tagName":...